Immunohistochemical characterization of subtypes of male breast carcinoma.
BACKGROUND
Male breast cancer accounts for around 1% of all breast cancer cases but the incidence has risen in recent years. This study aimed to classify the molecular subtypes of male breast cancers based on the expression profile of immunomarkers and to evaluate their association with clinicopathological features and expression patterns of epidermal growth factor receptor (EGFR) and nuclear factor kappaB (NF-kappaB).


METHODS
A total of 42 cases of male breast carcinoma were examined retrospectively using immunostains for estrogen receptor (ER), progesterone receptor (PR), cytokeratin 5/6 (CK5/6), EGFR, and NF-kappaB. Human epidermal growth factor receptor 2 (HER2) expression was evaluated by immunostaining and confirmed by fluorescent in situ hybridization (FISH).


RESULTS
The luminal A subtype was the most common subtype in male breast cancer (83%, 35/42), which was followed by the luminal B subtype (17%, 7/42). Basal-like and HER2+/ER- subtypes were not identified in this group. All carcinomas expressed ER and 67% of them were PR+. High nuclear grades were more common in the luminal B subtype (71%, 5/7) than in the luminal A subtype (34%, 12/35). The luminal B subtype carcinomas expressed EGFR (42%, 3/7) and NF-kappaB (57%, 4/7) more frequently than the luminal A subtype did (17%, 6/35 and 37%, 13/35, respectively).


CONCLUSIONS
In our study group, luminal A and B subtypes were the major subtypes of male breast carcinoma. The immunophenotypical features of male breast cancer differ from those of its female counterpart. Luminal B subtype tended to have high nuclear grade and more frequent expression of EGFR and NF-kappaB.
Department of Pathology, The Methodist Hospital, Weill Medical College of Cornell University, Houston, TX 77030, USA. yge@tmhs.org
Yimin
Y
Ge
Nour
N
Sneige
Mahmoud A
MA
Eltorky
Zhiqin
Z
Wang
E
E
Lin
Yun
Y
Gong
Ming
M
Guo
D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000145:classification / Q000378:metabolism* / Q000473:pathology*; D066246:ErbB Receptors / Q000096:biosynthesis; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D017404:In Situ Hybridization, Fluorescence; D053555:Keratin-5 / Q000096:biosynthesis; D053553:Keratin-6 / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000096:biosynthesis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis
D066246:ErbB Receptors; D053555:Keratin-5; D053553:Keratin-6; D016328:NF-kappa B; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human